Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by ggh2257on Sep 02, 2017 5:50pm
306 Views
Post# 26651076

RE:Time to buy

RE:Time to buySah1,

I'm also confident PLI will have great success in the near future, as you said cash positive in 2019. For myself, I don't expect much out of the small molecule side of the business before end of 2018 as most of these new Phase 2/3 studies are placebo and doubleblind. Partners may want to see the results before commiting big money. PL won't let go for a few $100M on these IPF and DKD, so it's going to take more time. I'm still puzzled of why we haven't seen the remaining of the first 12 weeks on IPF, maybe it's part of an agreement between a partner and PlI. I mean, keeping the results private until they reach an agreement? Have I missed this data?

The excitting part for me is really PPPS. After Pg, I expect the next BLA should go faster. I'm sure the team has learned working closely with the FDA. And we will see many more proteins scaled up the process. Not too far away, they will have to start a second line for PPPS and expand to Belleville. 

BTW, I've emailed Fred and asked about the FDA visit, would it be public info. He said it's going to be released and "very probably way sooner than the FDA approval". That's translated from french " fort probablement plus tt"... He didn't give a date, but I expect in the coming weeks. 

As for all these new wanabe ( few thousand shares) shorters, it's all noise! Nothing really worth discussing...

GLTA



Bullboard Posts